For the quarter ended December 2024, BioMarin Pharmaceutical (BMRN) reported income of $747.31 million, up 15.7% over the identical interval final 12 months. EPS got here in at $0.92, in comparison with $0.49 within the year-ago quarter.
The reported income compares to the Zacks Consensus Estimate of $711.93 million, representing a shock of +4.97%. The corporate delivered an EPS shock of +26.03%, with the consensus EPS estimate being $0.73.
Whereas traders carefully watch year-over-year adjustments in headline numbers — income and earnings — and the way they examine to Wall Road expectations to find out their subsequent plan of action, some key metrics at all times present a greater perception into an organization’s underlying efficiency.
Since these metrics play a vital function in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps traders higher undertaking a inventory’s value efficiency.
Right here is how BioMarin carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Revenues- Web product revenues: $735.63 million in comparison with the $703.50 million common estimate primarily based on 10 analysts. The reported quantity represents a change of +16.2% 12 months over 12 months.
- Revenues- Royalty and different revenues: $11.68 million versus $10.07 million estimated by 9 analysts on common. In comparison with the year-ago quarter, this quantity represents a -10.6% change.
- Revenues- Web Product Revenues- NAGLAZYME: $110 million in comparison with the $122.60 million common estimate primarily based on eight analysts. The reported quantity represents a change of +11.9% 12 months over 12 months.
- Revenues- Web Product Revenues- VIMIZIM: $191 million versus $181.70 million estimated by eight analysts on common. In comparison with the year-ago quarter, this quantity represents a +8.8% change.
- Revenues- Web Product Revenues- PALYNZIQ: $100 million in comparison with the $94.03 million common estimate primarily based on eight analysts. The reported quantity represents a change of +13.9% 12 months over 12 months.
- Revenues- Web Product Revenues- VOXZOGO: $208 million versus the eight-analyst common estimate of $201.90 million. The reported quantity represents a year-over-year change of +42.8%.
- Revenues- Web Product Revenues- ROCTAVIAN: $11 million in comparison with the $8.06 million common estimate primarily based on eight analysts.
- Revenues- Web Product Revenues- KUVAN: $28 million versus the eight-analyst common estimate of $23.55 million. The reported quantity represents a year-over-year change of -23.7%.
- Revenues- Web Product Revenues- ALDURAZYME: $39 million in comparison with the $28.13 million common estimate primarily based on eight analysts. The reported quantity represents a change of -8.7% 12 months over 12 months.
- Revenues- Web Product Revenues- BRINEURA: $48 million in comparison with the $43.36 million common estimate primarily based on eight analysts. The reported quantity represents a change of +10.1% 12 months over 12 months.
View all Key Company Metrics for BioMarin here>>>
Shares of BioMarin have returned +3.7% over the previous month versus the Zacks S&P 500 composite’s +2.4% change. The inventory at the moment has a Zacks Rank #2 (Purchase), indicating that it might outperform the broader market within the close to time period.
Zacks’ Analysis Chief Names “Inventory Most Prone to Double”
Our crew of consultants has simply launched the 5 shares with the best chance of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This high choose is among the many most modern monetary companies. With a fast-growing buyer base (already 50+ million) and a various set of leading edge options, this inventory is poised for giant positive factors. In fact, all our elite picks aren’t winners however this one might far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
